Dosing fundamentals Administration: Once weekly subcutaneous injection Same day each week (consistency matters) Preferably at the same time of day Half-life: Approximately 6 days, supporting weekly dosing Dose escalation: Every 4 weeks, unless: Side effects require holding current dose Individual tolerance suggests faster/slower progression Healthcare provider recommends adjustment Clinical trial doses tested The Phase 2 obesity trial tested multiple dosing arms: Key insight: 8 mg produces nearly the same results as 12 mg with fewer side effectsmaking it a potential "sweet spot" for many users
The Bottom Line Patients should have clear information about what these drugs can and cannot do, along with proper medical supervision that goes beyond just tracking weight, looking at muscle mass, nutrition, and overall health
While these drugs may help people on their journey, it is important to understand the potential for unwanted side effects when using them
While Wegovy for weight loss significantly reduces appetite, it doesnt fully suppress hunger immediately
With proper protein intake and resistance training, patients can maintain healthy lean mass while losing significant fat
Long-Term Safety Data Retatrutides long-term safety profile is not yet fully characterized